<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268121</url>
  </required_header>
  <id_info>
    <org_study_id>NEONEC D19-01</org_study_id>
    <nct_id>NCT04268121</nct_id>
  </id_info>
  <brief_title>Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas</brief_title>
  <acronym>NEONEC</acronym>
  <official_title>Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation ARCAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant&#xD;
      chemotherapy in patients with locally differentiated digestive NEC. The recommended&#xD;
      chemotherapy is based on the current reference combination of platinum (cisplatin or&#xD;
      carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to&#xD;
      avoid the morbidity of conventional surgery.&#xD;
&#xD;
      The objective of the study is to improve relapse-free survival (RFS) in NEC patients treated&#xD;
      with neoadjuvant chemotherapy followed by surgery or chemoradiotherapy.&#xD;
&#xD;
      In parallel, we will perform a prospective cohort study with patients whose diagnosis is made&#xD;
      during surgery, who have not received neoadjuvant treatment, and who are offered an adjuvant&#xD;
      treatment of the same type (combination of platinum and platinum salts and etoposide).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 48 patients is to be included in phase II and 30 patients in prospective cohort&#xD;
      during the inclusion period of phase II.&#xD;
&#xD;
      Phase II study treatment:&#xD;
&#xD;
      Neoadjuvant chemotherapy: Administration of 4 cycles of chemotherapy (3 months) with platinum&#xD;
      based chemotherapy (carboplatin or cisplatin, at the choice of the investigator) + etoposide.&#xD;
&#xD;
      Surgery or chemoradiotherapy depending on the tumor localization (the irradiation modalities&#xD;
      and associated chemotherapy treatment will be left to the discretion of the referring&#xD;
      radiotherapists according to current recommendations for each localization).&#xD;
&#xD;
      Prospective cohort:&#xD;
&#xD;
        -  Surgery (prior to study entry)&#xD;
&#xD;
        -  Adjuvant chemotherapy : Administration of 4 cycles of chemotherapy (3 months) with&#xD;
           platinum based chemotherapy (carboplatin or cisplatin, at the choice of the&#xD;
           investigator) + etoposide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II and prospective cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival (RFS) - phase II</measure>
    <time_frame>At 12 months</time_frame>
    <description>Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival (RFS) - prospective cohort</measure>
    <time_frame>At 12 months</time_frame>
    <description>Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient in response in pre-operative or prior radiochemotherapy (if applicable) - Phase II</measure>
    <time_frame>At 3 months after the beginning of treatment (up to 36 months)</time_frame>
    <description>according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II</measure>
    <time_frame>Up to 39 months</time_frame>
    <description>Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients operated after neoadjuvant chemotherapy or receiving radiochemotherapy (if applicable) - Phase II</measure>
    <time_frame>Up to 39 months</time_frame>
    <description>Number of patients operated after neoadjuvant chemotherapy or receiving</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - Phase II</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - Prospective cohort</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Phase II</measure>
    <time_frame>Up to 43 months</time_frame>
    <description>Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs.&#xD;
Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort</measure>
    <time_frame>Up to 43 months</time_frame>
    <description>Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs.&#xD;
Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Neuroendocrine Carcinoma</condition>
  <condition>Digestive Cancer</condition>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant treatment</intervention_name>
    <description>4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy</description>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant treatment</intervention_name>
    <description>Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase II&#xD;
&#xD;
          1. Histologically proven digestive CNE, (the WHO 2017 classification: poorly&#xD;
             differentiated and Ki 67 &gt; 20%),&#xD;
&#xD;
          2. Patients with localized CNE, without metastasis (computed tomography [CT],&#xD;
             thoraco-abdominopelvic CT scan [TAP] according to RECIST 1.1; examinations performed&#xD;
             no later than 21 days before starting the study treatment, possible locoregional lymph&#xD;
             node involvement defined according to the TNM classification),&#xD;
&#xD;
          3. Positron emission tomography (PET) and CT for lymph node status and elimination of&#xD;
             secondary visceral and/or bone disorders, 4. Resectable tumor, according to the&#xD;
             consensus decision made during local multidisciplinary surgical consultation meeting,&#xD;
&#xD;
        5. Age ≥ 18 years, 6. Written informed consent obtained from the patient, willing and able&#xD;
        to comply with the protocol, 7. Registration in a National Health Care System (Protection&#xD;
        Universelle Maladie [PUMa] included), 8. For female patients of childbearing potential,&#xD;
        negative pregnancy test within 7 days before starting the study treatment.&#xD;
&#xD;
        Men and women are required to use a reliable and adequate birth control during the study&#xD;
        (if applicable) during the period of treatment and during 6 months from the last treatment&#xD;
        administration.&#xD;
&#xD;
        Prospective cohort&#xD;
&#xD;
          1. Patients with localized digestive CNE histologically proven on the operative specimen&#xD;
             (the WHO 2017 classification: poorly differentiated and Ki 67&gt; 20%),&#xD;
&#xD;
          2. Localized, without metastasis on computed tomography [CT], thoracoabdominopelvic CT&#xD;
             scan [TAP] RECIST 1.1, and/or locoregional lymph node involvement,&#xD;
&#xD;
          3. Age ≥ 18 years,&#xD;
&#xD;
          4. Written informed consent obtained from the patient, willing and able to comply with&#xD;
             the protocol,&#xD;
&#xD;
          5. Registration in a National Health Care System (PUMa - Protection Universelle Maladie&#xD;
             included),&#xD;
&#xD;
          6. For female patients of childbearing potential, negative pregnancy test within 7 days&#xD;
             before starting the study treatment.&#xD;
&#xD;
        Men and women are required to use a reliable and adequate birth control methods during the&#xD;
        study (if applicable) during the period of treatment and during 6 months from the last&#xD;
        treatment administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase II&#xD;
&#xD;
          1. Well-differentiated NEC, whatever the grade,&#xD;
&#xD;
          2. Metastatic disease,&#xD;
&#xD;
          3. Cancer of unknown primary&#xD;
&#xD;
          4. Organ failure that does not allow chemotherapy treatment,&#xD;
&#xD;
          5. Previous malignancy within 5 years prior to the study except for cutaneous basal cell&#xD;
             carcinoma and uterine cancer in situ&#xD;
&#xD;
          6. Tumor with a mixed component (component accounts for ≥ 30%),&#xD;
&#xD;
          7. Patient impossible to follow-up,&#xD;
&#xD;
          8. Other than platinum-etoposide chemotherapy administrated,&#xD;
&#xD;
          9. Tutelage or guardianship or patient protected by law&#xD;
&#xD;
        Prospective cohort&#xD;
&#xD;
          1. Well-differentiated NEC, whatever the grade,&#xD;
&#xD;
          2. Metastatic disease,&#xD;
&#xD;
          3. Cancer of unknown primary&#xD;
&#xD;
          4. Organ failure that does not allow chemotherapy treatment,&#xD;
&#xD;
          5. Previous malignancy within 5 years prior to the study except for cutaneous basal cell&#xD;
             carcinoma and uterine cancer in situ&#xD;
&#xD;
          6. Tumor with a mixed component (component accounts for ≥ 30%),&#xD;
&#xD;
          7. Patient impossible to follow-up,&#xD;
&#xD;
          8. Other than platinum-etoposide chemotherapy administrated,&#xD;
&#xD;
          9. Tutelage or guardianship or patient protected by law.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
      <phone>+33(0)322088854</phone>
      <email>hautefeuille.vincent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien CALCAGNO, MD</last_name>
      <phone>+33(03)70632153</phone>
      <email>fabien.calcagno@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabien CALCAGNO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia HENTIC, MD</last_name>
      <phone>+ 33 (0)1 40 87 52 41</phone>
      <email>olivia.hentic@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivia HENTIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Côme LEPAGE, MD</last_name>
      <phone>+33 (0)3 80 39 33 40</phone>
      <email>come.lepage@u-bourgogne.fr</email>
    </contact>
    <investigator>
      <last_name>Côme LEPAGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas WALTER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas WALTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia NICCOLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia NICCOLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna PELLAT</last_name>
      <phone>+33 (0) 1 49 28 23 45</phone>
      <email>anna.pellat@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pauline AFCHAIN</last_name>
      <phone>+33 (0) 1 49 28 23 45</phone>
      <email>pauline.afchain@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier DUBREUIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain CORIAT, md</last_name>
    </contact>
    <investigator>
      <last_name>Romain CORIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline AFCHAIN, MD</last_name>
      <phone>+33 (0)1 49 28 23 29</phone>
      <email>pauline.afchain@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pauline AFCHAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis SMITH, MD</last_name>
      <phone>+ 33 (0)5 57 65 64 39</phone>
      <email>denis.smith@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Denis SMITH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
      <phone>+33(05)49443751</phone>
      <email>David.TOUGERON@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, MD</last_name>
      <phone>+33 (0)561779649</phone>
      <email>guimbaud.r@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Rosine GUIMBAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel DUCREUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michel DUCREUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

